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ABSTRACT 
Telmisartan is currently reported for inhibiting cervical cancer cells. Despite favorable therapeutic profile, poor aqueous solubility and low oral 
bioavailability limit its therapeutic application in treatment of cervical cancer. Telmisartan was chemically conjugated to poly (ethylene glycol) 
through amide linkage to form telmisartan-PEG drug conjugate. Poly (ethylene glycol) with terminal –NH2 was conjugated with telmisartan via 
amide linkage. Telmisartan-PEG conjugate displayed peak at 1690 cm-1 for C=O group of amide linkage. Furthermore, telmisartan illustrated the 
crystalline lattice as compared to amorphous nature of telmisartan-PEG conjugate. The in vitro dissolution testing indicated that telmisartan 
displayed only 22.6±3.8% drug release from dialysis bag as compared (Two-way ANOVA test, P<0.05) to 76.9±5.4% from telmisartan-PEG 
conjugate. The therapeutic efficacy of telmisartan and telmisartan-PEG conjugate was analyzed in cervical cancer, HeLa cells. The IC50 of 
telmisartan in HeLa cells was estimated to be 48.6±6.9µM as compared (Two Way ANOVA test) to 17.2±2.7-µM of telmisartan-PEG conjugate 
dissolved in aqueous phase. In conclusion, telmisartan-PEG conjugate must be investigated under a set of stringent in vivo parameters for 
pharmacokinetic and pharmacodynamic studies.   
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INTRODUCTION 
Telmisartan is currently used by several researchers for 
inhibiting cervical cancer cells.  It acts by antagonizing 
endothelial growth factor (VEGF) production. In addition, it 
is also an angiotensin receptor II type 1 antagonist and 
displays PPARγ receptor activation. Despite favorable 
therapeutic potential, poor aqueous solubility (0.078 
mg/mL) and low oral bioavailability (45-58%) limit its 
therapeutic application in treatment of cervical cancer.  
Several nanoscaled drug delivery systems including 
liposomes, nanoparticles were developed to improve the 
therapeutic efficacy of telmisartan in cervical cancer cells.1-3 
However, each drug delivery systems has its own pros and 
cons which limit their efficacy as a potent drug delivery 
system. Poly (ethylene glycol, PEG)-drug conjugates have 
been widely employed to improve drug permeability, 
dissolution and oral bioavailability of small and 
supramolecules.4,5 
Therefore in current investigation, telmisartan was 
chemically conjugated to poly (ethylene glycol) through 
amide linkage to form telmisartan-PEG drug conjugate. 
Furthermore, telmisartan-PEG drug conjugate was 
characterized under a set of stringent parameters to exhibit 
its utility against cervical cancer, HeLa cells.  
MATERIALS AND METHODS 
Telmisartan (TEL) was a kind gift sample from Swiss Garnier 
Life Sciences, India. Poly (ethylene glycol) of molecular 
weight 2000 with terminal –NH2 was purchased from Sigma-
Aldrich, USA. Dicyclohexyl carbodiimide (DCC) and N-
hydroxysuccinimide (NHS) were procured from Loba 
Chemie, Mumbai, India. All other chemicals used were of the 
highest analytical grade. 
Synthesis of telmisartan-PEG conjugate 
Poly (ethylene glycol) with terminal –NH2 was conjugated 
with telmisartan via amide linkage.6 Briefly, telmisartan (100 
mg, 0.233 M) was solubilized in 10 ml of tetrahydrofuran 
Sharma et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2019; 9(1):358-361 
ISSN: 2250-1177                                                                                   [359]                                                                                     CODEN (USA): JDDTAO 
(THF) and subsequently 200 mg of DCC and 200 mg of NHS 
was added to the solution under constant stirring. The 
reaction was held for 6 h at room temperature. After that, 
100 mg of PEG-NH2 was incorporated to the mixture and 
stirring was continued for another 24 h at room 
temperature. Finally, the mixture was dialyzed against 
distilled water (MWCO~10 kDa) for 24 h to remove un-
reacted components. The product was precipitated by adding 
3 ml of distilled water and subsequently centrifuged at 
10,000 rpm to get the final pellet. The pellet of telmisartan-
PEG conjugate was washed twice and stored in vacuum 
dessicator.   
Characterization of telmisartan-PEG conjugate 
Fourier-transforms infrared (FT-IR) spectroscopy 
The Synthesis of telmisartan-PEG conjugate was confirmed 
by employing FT-IR. FTIR spectrum of pure drug telmisartan 
and telmisartan-PEG conjugate was recorded at a scanning 
range of 400-4000 cm-1 with a resolution of 4 cm-1. Each 
sample was prepared into KBR disc with hydrolic press at a 
force of 40 psi for 4 min. 
Powder X-ray diffraction pattern 
Polymorphic state of the drug into nano-size range self-
assembled micelles was assessed by powder x-ray 
diffractometer (Ultima-4, Rigaku Company, Japan) with Ni-
filtered, Cu K-radiation, a voltage of 60 kV and a current of 50 
mA. The crystalline nature of pure drug telmisartan, physical 
mixture of drug and excipients, blank SAN and TEL-PEG-SAN 
were qualitatively analyzed by scanning powder sample over 
a range of diffraction angel between 5 to 50° at a rate of 
1°/min (Aslam et Al. 2016; Puri et al. 2016; Sharma et al. 
2017; Dixit et al. 2015) 
Scanning electron microscopy 
Telmisartan and telmisartan-PEG conjugate were examined 
by a scanning electron microscope (SEM) to visualize the 
surface topography. Samples were prepared by preparing 
the film on an aluminum stub. The stubs were then coated 
with gold to a thickness of 200–500 ˚A under an argon 
atmosphere using a gold sputter module in a high vacuum 
evaporator. The coated samples were scanned, and 
photographs were taken with a SEM (Jeol-1761, Cambridge, 
UK) camera. 
In vitro dissolution study 
Release pattern of pure telmisartan and relmisartan-PEG 
conjugate was quantitatively determined by dialysis tubing 
method in phosphate buffer solution, pH 6.8 at different time 
intervals.7 An accurately weighed quantity 40 mg of 
telmisartan and telmisartan-PEG conjugate (~40 mg of 
telmisartan) was suspended separately into 5 ml of 
phosphate buffer of 6.8 pH and added in dialysis tubing. The 
dialysis bags were then dispersed in 900 ml of phosphate 
buffer 6.8 pH and maintained at 37°C and 50 rpm as 
recommended for dissolution testing of oral products. At 
predetermined specified time intervals, 5 ml of dissolution 
medium was withdrawn and replaced with equal volume to 
maintain sink conditions. The aliquots were filtered through 
0.22µm membrane filter and absorbance of the filtrate was 
measured at 298 nm.3 
Standard cell proliferation assay 
A standard colorimetric MTT assay, as an in vitro cytotoxicity 
assay, was employed to investigate the cell cytotoxicity effect 
against HeLa cells.7 In brief, HeLa cells was seeded in 200-µL 
of DMEM medium and incubated for 24 h. Post incubation 
period of 24 h, medium was replaced with serum free DMEM 
medium. The HeLa cells were incubated with a gradient 
concentration of telmisartan and telmisartan-PEG conjugate 
equivalent to 20-100 µM concentration of telmisartan for 72 
h. After that, 0.50 mg/ml quantity of MTT dye was added to 
each well and incubated for a period of 4 h at 37°C. 
Subsequently, crystals were dissolved in 100-µL of DMSO. 
The absorbance of the mixture was determined at 570 nm 
and 630 nm as a reference wavelength by employing ELISA 
reader. All steps of the Study were carried out in triplicates. 
RESULTS AND DISCUSSION 
 
Figure 1: FT-IR spectrum of telmisartan, PEG-NH2 and 
telmisartan-PEG conjugate. 
In the current investigation, we have carried out the 
synthesis of telmisartan-PEG conjugate using covalent 
coupling chemistry. The carboxylic acid group of telmisartan 
was covalently coupled to amino functional group of poly 
ethylene glycol via amide linkage in order to improve 
dissolution profile and permeability in cervical cancer cells. 
Synthesis of telmisartan-PEG conjugate was verified by FT-IR 
spectroscopy (Figure 1).  FTIR spectrum of telmisartan 
displayed characteristic peaks at 3335.13 cm-1, 2991.31 cm-1, 
and 1696.04 cm-1, indicating the presence of functional 
aromatic C-H stretch, aliphatic C-H stretch, and carboxylic 
acid, respectively. Correspondingly, mPEG-NH2 displayed 
peaks at 3180 cm-1 and 1530 cm-1 for N-H stretching and N-H 
bending of amino group. Telmisartan-PEG conjugate 
displayed peak at 1690 cm-1 for C=O group of amide linkage.  
The crystalline state of telmisartan and telmisartan-PEG 
conjugate was elected confirmed by PXRD technique. XRD 
diffractogram of telmisartan demonstrated sharp peaks of 
higher intensity illustrated crystalline structure. However, 
telmisartan-PEG conjugate led to transformation of sharp 
peaks of high intensity to less diffused peak with very low 
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intensity (Figure 2). This confirmed the amorphization and 
micronization of drug in telmisartan-PEG conjugate. This was 
also confirmed by scanning electron microscopy (Figure 3). 
Photomicrograph of telmisartan illustrated the crystalline 
lattice as compared to amorphous nature of telmisartan-PEG 
conjugate. The in vitro dissolution testing indicated that 
telmisartan displayed only 22.6±3.8% drug release from 
dialysis bag as compared (Two-way ANOVA test, P<0.05) to 
76.9±5.4% from telmisartan-PEG conjugate (Figure 4).
 
 
Figure 2: XRD pattern of telmisartan and telmisartan-PEG conjugate 
 
Figure 3: Scanning electron microscopy of telmisartan and telmisartan-PEG conjugate 
 
Figure 4: In vitro dissolution testing of telmisartan and telmisartan-PEG conjugate 
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Figure 5: Measurement of IC50 value of telmisartan and telmisartan-PEG conjugate using standard cell proliferation assay 
against cervical cancer HeLa cells 
 
The high dissolution profile may be attributed to high 
solubility of PEG analogue in aqueous phase that ultimately 
augmented dissolution profile. The therapeutic efficacy of 
telmisartan and telmisartan-PEG conjugate was analyzed in 
cervical cancer, HeLa cells. The IC50 of telmisartan in HeLa 
cells was estimated to be 48.6±6.9µM as compared (Two 
Way ANOVA test) to 17.2±2.7-µM of telmisartan-PEG 
conjugate dissolved in aqueous phase (Figure 5). The low 
IC50 value may be attributed to higher solubility and 
permeability of telmisartan-PEG conjugate as compared to 
lipophilic (Log P~3.2) character of telmisartan.8-9   
CONCLUSION 
In conclusion, telmisartan-PEG conjugate may be scaled up 
with high yield using minimum efforts. Further, telmisartan-
PEG conjugate displayed high dissolution profile that may 
ultimately augment oral bioavailability and permeability 
across intestinal absorption window. Owing to desirable 
features, telmisartan-PEG conjugate exhibited low IC50 in 
cervical cancer cells. Therefore, telmisartan-PEG conjugate 
must be investigated under a set of stringent in vivo 
parameters for pharmacokinetic and pharmacodynamic 
studies.   
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